EUVIMEDEUVIMED entdecken
VergleichsstudieEvaluationsstudie

Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor–platelet interaction

Paola Colpani, Luciano Baronciani, Ilaria Mancini, Cristina Novembrino, Anna Lecchi, Giovanna Cozzi, Pasqualina De Leo, Massimo Boscolo Anzoletti, Silvia La Marca, Marco Boscarino, Maria Teresa Pagliari, Andrea Artoni und 1 weitere

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2025.08.020 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Paola Colpani und 12 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy. Hauptthemen laut MEDLINE: von Willebrand Factor, Blood Platelets, Single-Domain Antibodies, Purpura, Thrombotic Thrombocytopenic. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Ministry of Health, European Commission, Istituto di Ricovero e Cura a Carattere Scientifico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Caplacizumab, a humanized anti-von Willebrand factor (VWF) Nanobody, is used for immune-mediated thrombotic thrombocytopenic purpura (iTTP) treatment. Its binding to the VWF A1 domain inhibits VWF interaction with platelet glycoprotein (GP)Ib, counteracting microthrombosis and accelerating the normalization of the platelet count. In caplacizumab-treated patients with iTTP with bleeding episodes, measuring platelet-dependent VWF activity (VWF activity) is crucial for monitoring treatment with VWF concentrates. This activity, traditionally assessed by the VWF-ristocetin cofactor assay (VWF:RCo), nowadays could be evaluated with alternative methods as gain-of-function mutant GPIb binding assay (VWF:GPIbM), ristocetin-triggered GPIb binding assay (VWF:GPIbR), and monoclonal antibody binding-based VWF activity (VWF:Ab). OBJECTIVES: This study aimed to evaluate the capacity of 5 VWF activity assays to measure caplacizumab in vivo inhibitory effect on VWF-GPIb interaction. METHODS: In total, 17 patients with iTTP treated effectively with caplacizumab, as demonstrated by normal platelet counts, were assessed by VWF activity using 5 commercially available assays. Three patients were further evaluated with the total thrombus analysis system (T-TAS). RESULTS: Patients treated with caplacizumab showed no VWF activity using VWF:GPIbM and VWF:RCo assays. The VWF:Ab assay produced the highest values, while both VWF:GPIbR assays showed reduced VWF activity levels, although not to the extent of VWF:GPIbM and VWF:RCo. In patients analyzed by T-TAS no capillary occlusion was observed, indicating complete inhibition of the VWF-GPIb interaction by caplacizumab. CONCLUSION: The VWF:GPIbM and VWF:RCo appear to be the most suitable assays for monitoring VWF activity in patients with iTTP undergoing treatment with caplacizumab, as confirmed by T-TAS analysis. The VWF:GPIbR assays may be useful, but have a limited ability to detect caplacizumab's inhibition. The VWF:Ab assay is unsuitable for this purpose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Willebrand FactorBlood PlateletsSingle-Domain AntibodiesPurpura, Thrombotic ThrombocytopenicPlatelet Function TestsDrug MonitoringHumansFemaleMaleMiddle AgedPredictive Value of TestsProtein BindingPlatelet Glycoprotein GPIb-IX ComplexAdultAgedTreatment OutcomeReproducibility of Results

Stichwörter der Autor:innen

caplacizumabclinical laboratory techniquesthrombotic thrombocytopenic purpuratotal thrombus-formation analysis systemvon Willebrand factor

Substanzen

von Willebrand FactorcaplacizumabSingle-Domain AntibodiesPlatelet Glycoprotein GPIb-IX Complex

Autor:innen und Institutionen

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan…

Förderung

  • Ministry of Health
  • European Commission
  • Istituto di Ricovero e Cura a Carattere Scientifico

Zitieren

APA

Colpani, P., Baronciani, L., Mancini, I., Novembrino, C., Lecchi, A., Cozzi, G., De Leo, P., Anzoletti, M. B., La Marca, S., Boscarino, M., Pagliari, M. T., Artoni, A., & Peyvandi, F. (2025). Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor–platelet interaction. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.08.020

Vancouver

Colpani P, Baronciani L, Mancini I, Novembrino C, Lecchi A, Cozzi G, et al. Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor–platelet interaction. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.08.020

BibTeX
@article{Colpani2025,
  author = {Colpani, Paola and Baronciani, Luciano and Mancini, Ilaria and Novembrino, Cristina and Lecchi, Anna and Cozzi, Giovanna and De Leo, Pasqualina and Anzoletti, Massimo Boscolo and La Marca, Silvia and Boscarino, Marco and Pagliari, Maria Teresa and Artoni, Andrea and Peyvandi, Flora},
  title = {Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor–platelet interaction},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2025.08.020}
}
Kostenlos starten →